Get the Daily Brief
Latest Biotech News
AI Toolkit Flexynesis Advances Precision Oncology with Multi-Omics Data Integration
A research team led by Altuna Akalin at the Max Delbrück Center developed Flexynesis, an artificial intelligence-based toolkit for integrating multi-omics data and clinical information to improve...
MGI Tech Launches DNBSEQ-T7+ Ultra-High-Throughput Sequencing Platform
MGI Tech introduced the DNBSEQ-T7+, an upgraded sequencing system designed for advanced population genomics and multiomics research. The platform addresses the increasing data processing demands...
Accelerated Decline in US Neonatal Male Circumcision Rates from 2012 to 2022
A comprehensive Johns Hopkins study reveals a significant decline in neonatal male circumcision in the US over the past decade despite established clinical benefits. The analysis highlights...
Breakthrough in DNA Repair: Maria Jasin Awarded 2025 Pearl Meister Greengard Prize
Maria Jasin, PhD, recognized for pioneering research revealing how homologous recombination repairs DNA breaks and suppresses cancer development, won the 2025 Pearl Meister Greengard Prize. Her...
Post-Mortem Photon Counting CT and DNA Techniques Enhance Forensic Investigations
Emerging technologies are transforming forensic science with innovations like photon-counting computed tomography enabling improved rib fracture detection after death, and molecular assays using...
Bar-Ilan University and Sheba Medical Center Launch $120M Institute for Biotech Innovation
Bar-Ilan University and Sheba Medical Center in Israel announced a $120 million joint research institute in Ramat Gan’s Health Tech Valley to advance biomedical innovation. The institute aims to...
Novartis Doubles Down on Molecular Glue: $120M Upfront Deal with Monte Rosa
Novartis has expanded its collaboration with Monte Rosa Therapeutics, investing $120 million upfront for rights to a new molecular glue degrader targeting immune-mediated diseases. This second...
aTyr Pharma’s Efzofitimod Fails Phase 3 Pulmonary Sarcoidosis Trial, Stocks Crash
Biotechnology company aTyr Pharma announced its experimental drug efzofitimod did not meet the primary endpoint of reducing steroid use in a Phase 3 trial for pulmonary sarcoidosis, a debilitating...
Novo Nordisk Slashes Workforce by 9,000 Amid Mounting Competition and Market Challenges
Novo Nordisk revealed a restructuring plan that includes cutting approximately 9,000 jobs, around 11.5% of its global workforce, alongside management layer reductions aimed at strengthening...
US Health Secretary Kennedy Cuts $500M in mRNA Vaccine Research, Redirects Funding
US Health and Human Services Secretary Robert F. Kennedy Jr. has announced cancellation of approximately $500 million in funding for 22 mRNA vaccine research projects, including those targeting...
Breakthrough Fluorescence Probe Tracks Protein Microenvironment Changes in Living Cells
Researchers at Rice University developed a novel fluorescent probe named AnapTh, enabling real-time visualization of localized environmental changes within specific protein subdomains in living...
AI Toolkit Flexynesis Integrates Multi-Omics Data for Precision Oncology
A team led by Altuna Akalin at the Max Delbrück Center introduced Flexynesis, a deep learning toolkit designed for flexible integration of multi-omics datasets—including DNA, RNA, and protein...
MGI Tech Launches DNBSEQ-T7+ Ultra-High-Throughput Sequencing Platform
MGI Tech unveiled the DNBSEQ-T7+ sequencer, an advanced instrument aimed at meeting rising throughput demands in population genomics, multiomics, and precision medicine. This scalable platform...
Breakthrough Artificial Protein Combines Elasticity and Cell Signaling for Tissue Repair
A collaborative research team from POSTECH and Inha University developed a novel artificial protein that synergizes mechanical elasticity with cell signaling capabilities, markedly enhancing...
aTyr Pharma Plans FDA Talks After Efzofitimod Phase 3 Setback in Lung Disease
Despite the Phase 3 failure of efzofitimod to significantly reduce steroid dependence in pulmonary sarcoidosis, aTyr Pharma intends to engage regulatory authorities to explore possible pathways...
Novartis Deepens $5.7B Bet on Molecular Glue Degraders with Monte Rosa Deal
Novartis has expanded its collaboration with Monte Rosa Therapeutics by securing exclusive rights to a new molecular glue degrader drug candidate and options for two additional programs, paying...
aTyr Pharma’s Efzofitimod Fails Phase 3 Trial, Shares Collapse 80%
aTyr Pharma’s lead drug candidate efzofitimod missed its primary endpoint in a Phase 3 trial for pulmonary sarcoidosis, an inflammatory lung disease. The therapy failed to significantly reduce...
Novo Nordisk Announces 9,000 Job Cuts Amid Intensifying Market Competition
Novo Nordisk revealed plans to reduce its workforce by approximately 11.5%, cutting around 9,000 jobs globally as part of a major restructuring initiative. The move aims to streamline management...
FDA Approves Precigen’s Papzimeos for Recurrent Respiratory Papillomatosis
The FDA has granted full approval to Precigen’s Papzimeos (zopapogene imadenovec-drba), the first medical therapy for recurrent respiratory papillomatosis (RRP), a rare respiratory disorder caused...
AI Toolkit Flexynesis Advances Multi-Omics Integration for Precision Oncology
Researchers led by Altuna Akalin at the Max Delbrück Center developed Flexynesis, a deep learning toolkit designed to integrate multi-omics data alongside clinical and imaging information to...